Literature DB >> 1096802

Inhibition by levorphanol and related drugs of amino acid transport by isolated membrane vesicles from Escherichia coli.

M J Holland, E J Simon.   

Abstract

Levorphanol inhibits the transport of the amino acids proline and lysine by cytoplasmic membrane vesicles derived from Escherichia coli. The degree of inhibition increases with increasing levorphanol concentration and ranges from 26% at 10(-6) M levorphanol to 92% at 10(-3) M levorphanol. The effect is independent of the energy source, since levorphanol inhibits proline uptake to the same extent in the presence of 20 mM d-lactate or 20 mM succinate and in the absence of an exogenous energy source. Levorphanol does not irreversibly alter the ability of membrane vesicles to transport proline, since incubation of membrane vesicles for 15 min in the presence of 0.25 mM levorphanol, a concentration which inhibits proline transport by more than 75%, has no effect on the rate of proline transport by these vesicles once the drug is removed. Both the maximum velocity and the K(m) of proline transport are modified by levorphanol, hence, the type of inhibition produced by levorphanol is mixed. The inhibitor constant (K(i)) for levorphanol inhibition of proline transport is approximately 3 x 10(-4) M. Membrane vesicles incubated in the presence of levorphanol accumulate much less proline at the steady state than do control vesicles. Furthermore, the addition of levorphanol to membrane vesicles preloaded to the steady state with proline produces a marked net efflux of proline. Levorphanol does not block either temperature-induced efflux or exchange of external proline with [(14)C]proline present in the intravesicular pool. Dextrorphan, the enantiomorph of levorphanol, and levallorphan, the N-allyl analogue of levorphanol, inhibit proline and lysine transport in a similar manner. Possible mechanisms of the effects of these drugs on cell membranes are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1096802      PMCID: PMC429177          DOI: 10.1128/AAC.7.5.530

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  SELECTIVE INHIBITION OF SYNTHESIS OF RIBOSOMAL RNA IN ESCHERICHIA COLI BY LEVORPHANOL.

Authors:  E J SIMON; D VANPRAAG
Journal:  Proc Natl Acad Sci U S A       Date:  1964-06       Impact factor: 11.205

2.  INHIBITION OF RNA SYNTHESIS IN ESCHERICHIA COLI BY LEVORPHANOL.

Authors:  E J SIMON; D VANPRAAG
Journal:  Proc Natl Acad Sci U S A       Date:  1964-05       Impact factor: 11.205

3.  Mutants of Escherichia coli requiring methionine or vitamin B12.

Authors:  B D DAVIS; E S MINGIOLI
Journal:  J Bacteriol       Date:  1950-07       Impact factor: 3.490

Review 4.  Transport across isolated bacterial cytoplasmic membranes.

Authors:  H R Kaback
Journal:  Biochim Biophys Acta       Date:  1972-08-04

5.  The mode of action of levallorphan as an inhibitor of cell growth.

Authors:  R Greene; B Magasanik
Journal:  Mol Pharmacol       Date:  1967-09       Impact factor: 4.436

6.  Reversible inhibition of RNA phage replication and macromolecular synthesis by levorphanol.

Authors:  E J Simon; D J Garwes; J Rand
Journal:  Biochem Biophys Res Commun       Date:  1970-09-10       Impact factor: 3.575

7.  Effect of morphine derivatives on lipid metabolism in Staphylococcus aureus.

Authors:  E F Gale
Journal:  Mol Pharmacol       Date:  1970-03       Impact factor: 4.436

8.  Effects of diacetylmorphine and related morphinans on some biochemical activities of Staphylococcus aureus.

Authors:  E F Gale
Journal:  Mol Pharmacol       Date:  1970-03       Impact factor: 4.436

9.  Effect of levorphanol on putrescine transport in Escherichia coli.

Authors:  E J Simon; L Schapira; N Wurster
Journal:  Mol Pharmacol       Date:  1970-11       Impact factor: 4.436

10.  Effects of levorphanol on phospholipid metabolism and composition in Escherichia coli.

Authors:  N Wurster; P Elsbach; J Rand; E J Simon
Journal:  Biochim Biophys Acta       Date:  1971-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.